Lowest Price Guaranteed
Slides
198
Last Updated
July 2025
View Count
14841
EXCEL DELIVERABLE
1. INNOVATORS AND PRODUCTS DATASET
1.1. Analysis Notes
1.2. Innovator Landscape
1.3. Product Landscape
1.4. Value Proposition
1.5. Key Acquisition Targets
1.6. AI – AVII Appendices
2. FUNDING AND INVESTMENT ANALYSIS
2.1. Analysis Notes
2.2. Summary Dashboard
2.3. Capital Investments in Digital Therapeutics
2.4 AI – AIV Appendices
3. FUNDAMENTAL AND TECHNICAL FINANCIAL ANALYSIS
The information presented in this analysis is spread across separate MS Excel sheets, which provide information on key financial parameters and competitive insights based on historical and prevalent trends.
4. BUSINESS RISK ANALYSIS
4.1. Analysis Notes
4.2. Business Risk Data
4.3. AI – AVII Appendices
5. MARKET FORECAST AND OPPORTUNITY ANALYSIS
5.1. Analysis Notes
5.2. Market Forecast and Opportunity Analysis: Summary
5.3. Market Forecast and Opportunity Analysis: Base Scenario
5.4. Market Forecast and Opportunity Analysis: Conservative Scenario
5.5. Market Forecast and Opportunity Analysis: Optimistic Scenario
6. RETURN ON INVESTMENT
6.1. Analysis Notes
6.2. Estimated RoI for Investors in Company A
6.3. Estimated RoI for Investors in Company B
6.4. Estimated RoI for Investors in Company C
POWERPOINT DELIVERABLE
1. CONTEXT
2. PROJECT APPROACH
3. PROJECT OBJECTIVES
4. EXECUTIVE SUMMARY
Section I: Need for Digital Therapeutics and Innovators Landscape
5. THE DIGITAL THERAPEUTICS MARKET
5.1. Overview
5.2. Historical Milestones
5.3. Key Types of Solutions
5.4. Key Strategic Initiatives
5.5. Key Concepts, Marketed Products and Challenges
6. DIGITAL THERAPEUTICS: INNOVATOR LANDSCAPE
6.1. Methodology
6.2. Innovators in the Digital Therapeutics Market
6.3. Analysis of Competitive Landscape
6.4. Conclusion
7. DIGITAL THERAPEUTICS: PRODUCT LANDSCAPE AND COMPANY HEALTH INDEXING
7.1. List of Digital Therapeutics
7.2. Analysis of Product Landscape
7.3. Health Indexing Methodology
7.4. Company Health Indexing
8. VALUE PROPOSITION ANALYSIS
8.1. Overview and Methodology
8.2. Outreach-related Value
8.3. Developer Value
8.4. Product-related Value
8.5. Value to Patients
8.6. Concluding Remarks
9. COMPANY COMPETITIVENESS ANALYSIS
9.1. Overview and Methodology
9.2. Company Competitiveness Analysis
Section II Analysis of Investments
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Overview
10.2. Analysis by Type of Funding
10.3. Analysis by Geography and Most Active Players
10.4. Analysis of Trends Across Various Funding Categories
10.5. Summary of Funding and Investments
Section III Financial Analysis and Assessment of Business Risks
11. FINANCIAL ANALYSIS OF PUBLIC VENTURES
11.1. Fundamental Financial Analysis Overview
11.2. Financial Ratios (Interpretation Guide)
11.3. Case Study 1
11.4. Technical Financial Analysis Overview
11.5. Technical Indicators (Interpretation Guide)
11.6. Case Study 2
12. COMPANY PROFILES OF PUBLIC VENTURES
12.1 Akili Interactive
12.1.1. Key Highlights
12.1.1.1. Company Details
12.1.1.1. Company Overview
12.1.1.3. Insights from Balance Sheet
12.1.1.4. Management Team
12.1.1.5. Recent Developments
12.1.2. Key Financial Details
12.1.2.1. Company Investments
12.1.2.2. Company Fundamentals
12.1.2.3. Company Technicals
12.2. Better Therapeutics
12.2.1. Key Highlights
12.2.1.1. Company Details
12.2.1.1. Company Overview
12.2.1.3. Insights from Balance Sheet
12.2.1.4. Management Team
12.2.1.5. Recent Developments
12.2.2 Key Financial Details
12.2.2.1. Company Investments
12.2.2.2. Company Fundamentals
12.2.2.3. Company Technicals
12.3. Brain+
12.3.1. Key Highlights
12.3.1.1. Company Details
12.3.1.1. Company Overview
12.3.1.3. Insights from Balance Sheet
12.3.1.4. Management Team
12.3.1.5. Recent Developments
12.3.2. Key Financial Details
12.3.2.1. Company Investments
12.3.2.2. Company Fundamentals
12.3.2.3. Company Technicals
12.4. Dario Health
12.4.1. Key Highlights
12.4.1.1. Company Details
12.4.1.1. Company Overview
12.4.1.3. Insights from Balance Sheet
12.4.1.4. Management Team
12.4.1.5. Recent Developments
12.4.2 Key Financial Details
12.4.2.1. Company Investments
12.4.2.2. Company Fundamentals
12.4.2.3. Company Technicals
12.5. Ehave
12.5.1. Key Highlights
12.5.1.1. Company Details
12.5.1.1. Company Overview
12.5.1.3. Insights from Balance Sheet
12.5.1.4. Management Team
12.5.1.5. Recent Developments
12.5.2. Key Financial Details
12.5.2.1. Company Investments
12.5.2.2. Company Fundamentals
12.5.2.3. Company Technicals
12.6. Mindcure
12.6.1. Key Highlights
12.6.1.1. Company Details
12.6.1.1. Company Overview
12.6.1.3. Insights from Balance Sheet
12.6.1.4. Management Team
12.6.1.5. Recent Developments
12.6.2. Key Financial Details
12.6.2.1. Company Investments
12.6.2.2. Company Fundamentals
12.6.2.3. Company Technicals
12.7. Newtopia
12.7.1. Key Highlights
12.7.1.1. Company Details
12.7.1.1. Company Overview
12.7.1.3. Insights from Balance Sheet
12.7.1.4. Management Team
12.7.1.5. Recent Developments
12.7.2. Key Financial Details
12.7.2.1. Company Investments
12.7.2.2. Company Fundamentals
12.7.2.3. Company Technicals
12.8. Pear Therapeutics
12.8.1. Key Highlights
12.8.1.1. Company Details
12.8.1.1. Company Overview
12.8.1.3. Insights from Balance Sheet
12.8.1.4. Management Team
12.8.1.5. Recent Developments
12.8.2. Key Financial Details
12.8.2.1. Company Investments
12.8.2.2. Company Fundamentals
12.8.2.3. Company Technicals
12.9. Sharecare
12.9.1. Key Highlights
12.9.1.1. Company Details
12.9.1.1. Company Overview
12.9.1.3. Insights from Balance Sheet
12.9.1.4. Management Team
12.9.1.5. Recent Developments
12.9.2 Key Financial Details
12.9.2.1. Company Investments
12.9.2.2. Company Fundamentals
12.9.2.3. Company Technicals
13. BUSINESS RISK ANALYSIS
13.1. Overview and Methodology
13.2. Operations-related Risks
13.3. Business-related Risks
13.4. Financial / Asset-related Risks
13.5. Product / Technology Risks
13.6. Other Risks
13.7. Business Risk Summary
Section IV Market Forecast and Opportunity Analysis
14. MARKET FORECAST
14.1. Overview and Methodology
14.2. Global Digital Therapeutics Market, 2023-2035
14.3. Distribution Across Key Market Segments
14.3.1. Digital Therapeutics Market: Distribution by Type of Solution, 2023 and 2035
14.3.1.1. Digital Therapeutics Market for Standalone Software Application, 2023-2035
14.3.1.2. Digital Therapeutics Market for Combination Offerings (Software Application + Device), 2023-2035
14.3.1.3. Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), 2023-2035
14.3.1.4. Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2023-2035
14.3.1.5. Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2023-2035
14.3.1.6. Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2023-2035
14.3.1.7. Digital Therapeutics Market for Other Types of Solutions, 2023-2035
14.3.2. Digital Therapeutics Market: Distribution by Type of Therapy, 2023 and 2035
14.3.2.1. Digital Therapeutics Market for Curative Therapy, 2023-2035
14.3.2.2. Digital Therapeutics Market for Preventive Therapy, 2023-2035
14.3.3. Digital Therapeutics Market: Distribution by Therapeutic Area, 2023 and 2035
14.3.3.1. Digital Therapeutics Market for Cardiovascular Disorders, 2023-2035
14.3.3.2. Digital Therapeutics Market for Chronic Pain, 2023-2035
14.3.3.3 Digital Therapeutics Market for Mental Health Problems, 2023-2035
14.3.3.4 Digital Therapeutics Market for Metabolic Disorders, 2023-2035
14.3.3.5 Digital Therapeutics Market for Neurological Disorders, 2023-2035
14.3.3.6 Digital Therapeutics Market for Respiratory Disorders, 2023-2035
14.3.3.7 Digital Therapeutics Market for Sleep Disorders, 2023-2035
14.3.3.8 Digital Therapeutics Market for Substance Use Disorders, 2023-2035
14.3.3.9 Digital Therapeutics Market for Other Disorders, 2023-2035
14.3.4. Digital Therapeutics Market: Distribution by Geographical Regions, 2023 and 2035
14.3.4.1. Digital Therapeutics Market in North America, 2023-2035
14.3.4.2. Digital Therapeutics Market in Europe, 2023-2035
14.3.4.3. Digital Therapeutics Market in Asia-Pacific and Rest of the World, 2023-2035
Section V Analysis of Returns on Investment and Key Acquisition Targets
15. ANALYSIS OF RETURNS ON INVESTMENT
15.1. Overview and Methodology
15.2. Case Studies
16. KEY ACQUISITION TARGETS
16.1. Overview
16.2. List of Key Acquisition Targets
17. CONCLUSION
18. APPENDICES
Figure 5.1. Digital Therapeutics: Key Definitions and Background
Figure 5.2. Digital Therapeutics: Key Historical Milestones
Figure 5.3. Digital Therapeutics: Types of Solutions and Key Industry Players
Figure 5.4. Digital Therapeutics: Key Strategic Initiatives
Figure 5.5 Digital Therapeutics: Key Marketed Products and Challenges
Figure 6.1. Innovator Landscape: Distribution by Year of Establishment
Figure 6.2. Innovator Landscape: Distribution by Type of Venture
Figure 6.3. Innovator Landscape: Distribution by Company Size
Figure 6.4. Innovator Landscape: Distribution by Geography
Figure 7.1. Product Landscape: Distribution of Innovators by Number of Products
Figure 7.2. Product Landscape: Distribution by Type of Therapy
Figure 7.3. Product Landscape: Distribution of Products by Status of Development
Figure 7.4. Product Landscape: Distribution of Products by Type of Solution
Figure 7.5. Product Landscape: Distribution of Innovators by Therapeutic Area
Figure 8.1. Companies Offering Outreach-Related Value: Distribution of Companies by Value Offered and Experience
Figure 8.2. Companies Offering Outreach-Related Value: Analysis of Companies Offering Very High Value
Figure 8.3. Companies Offering Developer Value: Distribution of Companies by Value Offered and Experience
Figure 8.4. Companies Offering Developer Value: Analysis of Companies Offering Very High Value (2007-2013)
Figure 8.5. Companies Offering Developer Value: Analysis of Companies Offering Very High Value (2014 Onwards)
Figure 8.6. Companies Offering Product-related Value: Distribution of Companies by Value Offered and Experience
Figure 8.7. Companies Offering Product-related Value: Analysis of Companies Offering Very High Value
Figure 8.8. Companies Offering Value to Patients: Distribution of Companies by Value Offered and Experience
Figure 8.9. Companies Offering Value to Patients: Analysis of Companies Offering Very High Value
Figure 9.1. Competitiveness Analysis: Large Companies based in North America (Peer Group I)
Figure 9.2. Competitiveness Analysis: Mid-sized Companies based in North America (Peer Group II)
Figure 9.3. Competitiveness Analysis: Small Companies based in North America (Peer Group III)
Figure 9.4. Competitiveness Analysis: Very Small Companies based in North America (Peer Group IV)
Figure 9.5. Competitiveness Analysis: Large and Mid-sized Companies based in Europe (Peer Group V)
Figure 9.6. Competitiveness Analysis: Small Companies based in Europe (Peer Group VI)
Figure 9.7. Competitiveness Analysis: Very Small Companies based in Europe (Peer Group VII)
Figure 9.8. Competitiveness Analysis: Mid-sized Companies based in Asia-Pacific and Rest of the World (Peer Group VIII)
Figure 9.9. Competitiveness Analysis: Small Companies based in Asia-Pacific and Rest of the World (Peer Group IX)
Figure 9.10. Competitiveness Analysis: Very Small Companies based in Asia-Pacific and Rest of the World (Peer Group X)
Figure 10.1. Funding and Investment Analysis: Year-wise Distribution of Funding Instances and Amount Invested (2011-2022)
Figure 10.2. Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 10.3. Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding
Figure 10.4. Funding and Investment Analysis: Geographical Distribution
Figure 10.5. Funding and Investment Analysis: Most Active Players (Number of Instances)
Figure 10.6. Funding and Investment Analysis: Most Active Players (By Amount Raised)
Figure 10.7. Awards / Grants: Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.8. Awards / Grants: Geographical Distribution by Amount Invested
Figure 10.9. Awards / Grants: Most Active Investors
Figure 10.10. Seed Funding: Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.11. Seed Funding: Geographical Distribution by Amount Invested
Figure 10.12. Seed Funding: Most Active Investors
Figure 10.13. Private Placements: Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.14. Private Placements: Geographical Distribution by Amount Invested
Figure 10.15. Private Placements: Most Active Investors
Figure 10.16. Debt Financing: Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.17. Debt Financing: Geographical Distribution by Amount Invested
Figure 10.18. Debt Financing: Most Active Investors
Figure 10.19. Venture (Series A): Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.20. Venture (Series A): Geographical Distribution by Amount Invested
Figure 10.21. Venture (Series A): Most Active Investors
Figure 10.22. Venture (Series B): Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.23. Venture (Series B): Geographical Distribution by Amount Invested
Figure 10.24. Venture (Series B): Most Active Investors
Figure 10.25. Venture (Series C): Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.26. Venture (Series C): Geographical Distribution by Amount Invested
Figure 10.27. Venture (Series C): Most Active Investors
Figure 10.28. Venture (Series D): Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.29. Venture (Series D): Geographical Distribution by Amount Invested
Figure 10.30. Venture (Series D): Most Active Investors
Figure 10.31. Venture (Series E, F, G and Unknown): Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.32. Venture (Series E, F, G and Unknown): Geographical Distribution by Amount Invested
Figure 10.33. Venture (Series E, F, G and Unknown): Most Active Investors
Figure 10.34. Public Offering: Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.35. Public Offering: Geographical Distribution by Amount Invested
Figure 10.36. Public Offering: Most Active Investors
Figure 10.37. Capital Investments in Digital Therapeutics Company: Summary of Funding and Investments, 2011-2022
Figure 11.1. Fundamental Financial Analysis: Annual Revenues and Key Balance Sheet Parameter-related Trends
Figure 11.2. Fundamental Financial Analysis: Liquidity Ratios
Figure 11.3. Fundamental Financial Analysis: Financial & Business Risk Ratios and Turnover / Efficiency Ratios
Figure 11.4. Fundamental Financial Analysis: Profitability Ratios
Figure 11.5. Fundamental Financial Analysis: Market Value Ratios & Stability Ratios
Figure 11.6. Technical Financial Analysis: Stock Price (Candlestick Chart) and Volume Traded
Figure 11.7. Technical Financial Analysis: 5-Day Moving Average
Figure 11.8. Technical Financial Analysis: 10-Day Moving Average
Figure 11.9. Technical Financial Analysis: 50-Day Moving Average
Figure 11.10. Technical Financial Analysis: Bollinger Band®
Figure 11.11. Technical Financial Analysis: Relative Strength Index
Figure 11.12. Technical Financial Analysis: Commodity Channel Index
Figure 11.13. Technical Financial Analysis: MACD
Figure 11.14. Technical Financial Analysis: Williams’ R Analysis
Figure 11.15. Technical Financial Analysis: Average Directional Index (ADX)
Figure 12.1. Akili Interactive: Company Fundamentals
Figure 12.2. Akili Interactive: Trend of Stock Prices Since Initial Public Offering
Figure 12.3. Better Therapeutics: Company Fundamentals
Figure 12.4. Better Therapeutics: Trend of Stock Prices Since Initial Public Offering
Figure 12.5. Brain+: Company Fundamentals
Figure 12.6. Brain+: Trend of Stock Prices Since Initial Public Offering
Figure 12.7. Dario Health: Company Fundamentals
Figure 12.8. Dario Health: Trend of Stock Prices Since Initial Public Offering
Figure 12.9. Ehave: Company Fundamentals
Figure 12.10. Ehave: Trend of Stock Prices Since Initial Public Offering
Figure 12.11. Mindcure: Company Fundamentals
Figure 12.12. Mindcure: Trend of Stock Prices Since Initial Public Offering
Figure 12.13. Newtopia: Company Fundamentals
Figure 12.14. Newtopia: Trend of Stock Prices Since Initial Public Offering
Figure 12.15. Pear Therapeutics: Company Fundamentals
Figure 12.16. Pear Therapeutics: Trend of Stock Prices Since Initial Public Offering
Figure 12.17. Sharecare: Company Fundamentals
Figure 12.18. Sharecare: Trend of Stock Prices Since Initial Public Offering
Figure 13.1. Business Risk Analysis: Operations-related Risks
Figure 13.2. Business Risk Analysis: Business-related Risks
Figure 13.3. Business Risk Analysis: Financial / Asset-related Risks
Figure 13.4. Business Risk Analysis: Product / Technology Risks
Figure 13.5. Business Risk Analysis: Other Risks
Figure 13.6. Summary of Business Risk Analysis
Figure 14.1. Digital Therapeutics Market: Forecast, 2023-2035 (USD Million)
Figure 14.2. Digital Therapeutics Market: Distribution by Type of Solution, 2023 and 2035
Figure 14.3. Digital Therapeutics Market for Standalone Software Applications, 2023-2035 (USD Million)
Figure 14.4. Digital Therapeutics Market for Combination Offerings (Standalone Software Applications + Device), 2023-2035 (USD Million)
Figure 14.5. Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), 2023-2035 (USD Million)
Figure 14.6. Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2023-2035 (USD Million)
Figure 14.7. Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2023-2035 (USD Million)
Figure 14.8. Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2023-2035 (USD Million)
Figure 14.9. Digital Therapeutics Market for Other Types of Solutions, 2023-2035 (USD Million)
Figure 14.10. Digital Therapeutics Market: Distribution by Type of Therapy, 2023 and 2035
Figure 14.11 Digital Therapeutics Market for Curative Solutions, 2023-2035 (USD Million)
Figure 14.12 Digital Therapeutics Market for Preventive Solutions, 2023-2035 (USD Million)
Figure 14.13 Digital Therapeutics Market: Distribution by Therapeutic Area, 2023 and 2035
Figure 14.14 Digital Therapeutics Market for Cardiovascular Disorders, 2023-2035 (USD Million)
Figure 14.15 Digital Therapeutics Market for Pain Management, 2023-2035 (USD Million)
Figure 14.16 Digital Therapeutics Market for Mental Health Problems, 2023-2035 (USD Million)
Figure 14.17 Digital Therapeutics Market for Metabolic Disorders, 2023-2035 (USD Million)
Figure 14.18 Digital Therapeutics Market for Neurological Disorders, 2023-2035 (USD Million)
Figure 14.19 Digital Therapeutics Market for Respiratory Disorders, 2023-2035 (USD Million)
Figure 14.20 Digital Therapeutics Market for Sleep Disorders, 2023-2035 (USD Million)
Figure 14.21 Digital Therapeutics Market for Substance Use Disorders, 2023-2035 (USD Million)
Figure 14.22 Digital Therapeutics Market for Other Disorders, 2023-2035 (USD Million)
Figure 14.23 Digital Therapeutics Market: Distribution by Key Geographical Regions, 2023 and 2035
Figure 14.24 Digital Therapeutics Market in North America, 2023-2035 (USD Million)
Figure 14.25 Digital Therapeutics Market in Europe, 2023-2035 (USD Million)
Figure 14.26 Digital Therapeutics Market in Asia-Pacific and Rest of the World, 2023-2035 (USD Million)
Figure 16.1. Key Acquisition Targets: Comparison of Scores with Overall Dataset
Figure 16.2. Key Acquisition Targets: Comparison based on Qualifying Parameters (1/4)
Figure 16.3. Key Acquisition Targets: Comparison based on Qualifying Parameters (2/4)
Figure 16.4. Key Acquisition Targets: Comparison based on Qualifying Parameters (3/4)
Figure 16.5. Key Acquisition Targets: Comparison based on Qualifying Parameters (4/4)
Figure 17.1. Concluding Remarks: North America
Figure 17.2. Concluding Remarks: Europe
Figure 17.3. Concluding Remarks: Asia-Pacific and Rest of the World
Table 6.1. Key Innovators in the Digital Therapeutics Market
Table 7.1. Products Offered by Innovators in the Digital Therapeutics Market
Table 7.2. Company Health Indexing
Table 11.1. Fundamental Financial Analysis: List of Publicly Listed Digital Therapeutics Developers
Table 11.2. Technical Financial Analysis: List of Publicly Listed Digital Therapeutics Developers
Table 16.1 List of Digital Therapeutics Likely Acquisition Targets (Company Strength)
Table 16.2. List of Digital Therapeutics Likely Acquisition Targets (Value Proposition)
The following companies / institutes / government bodies and organizations have been mentioned in this report.
Please reach out to our team for more details.
Source 1: https://www.digital-adoption.com/digital-adoption-healthcare-research/
Source 2: https://sdlcpartners.com/insights/what-is-digital-therapeutics/